Narayan P, Osgood CL, Singh H, Chiu HJ, et al. FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of
unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res 2021 Mar 22. pii: 1078-0432.CCR-20-4557.
PMID: 33753456